These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 17419802)

  • 1. Use of proteomics for the identification of novel drug targets in brain diseases.
    Morón JA; Devi LA
    J Neurochem; 2007 Jul; 102(2):306-15. PubMed ID: 17419802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How proteomics reveals potential biomarkers in brain diseases.
    Schmidt O; Schulenborg T; Meyer HE; Marcus K; Hamacher M
    Expert Rev Proteomics; 2005 Dec; 2(6):901-13. PubMed ID: 16307519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Genomics meets neurodegenerative disorders. Part II: application and data integration.
    Hoerndli F; David DC; Götz J
    Prog Neurobiol; 2005 Jun; 76(3):169-88. PubMed ID: 16169146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avian proteomics: advances, challenges and new technologies.
    Doherty MK; McLean L; Beynon RJ
    Cytogenet Genome Res; 2007; 117(1-4):358-69. PubMed ID: 17675879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomics: recent applications and new technologies.
    Elrick MM; Walgren JL; Mitchell MD; Thompson DC
    Basic Clin Pharmacol Toxicol; 2006 May; 98(5):432-41. PubMed ID: 16635100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary methods to assist subcellular fractionation in organellar proteomics.
    Gauthier DJ; Lazure C
    Expert Rev Proteomics; 2008 Aug; 5(4):603-17. PubMed ID: 18761470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling brain drug delivery.
    Calabria AR; Shusta EV
    Drug Discov Today; 2006 Sep; 11(17-18):792-9. PubMed ID: 16935746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifunctional drugs with different CNS targets for neuropsychiatric disorders.
    Van der Schyf CJ; Geldenhuys WJ; Youdim MB
    J Neurochem; 2006 Nov; 99(4):1033-48. PubMed ID: 17054441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in neuromembrane proteomics: efforts towards a comprehensive analysis of membrane proteins in the brain.
    Grant KJ; Wu CC
    Brief Funct Genomic Proteomic; 2007 Mar; 6(1):59-69. PubMed ID: 17353200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics: present and future implications in neuro-oncology.
    Micallef J; Gajadhar A; Wiley J; DeSouza LV; Michael Siu KW; Guha A
    Neurosurgery; 2008 Mar; 62(3):539-55; discussion 539-55. PubMed ID: 18425004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative proteomics in neurodegenerative and non-neurodegenerative diseases suggest nodal point proteins in regulatory networking.
    Zabel C; Sagi D; Kaindl AM; Steireif N; Kläre Y; Mao L; Peters H; Wacker MA; Kleene R; Klose J
    J Proteome Res; 2006 Aug; 5(8):1948-58. PubMed ID: 16889417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteome analysis of the dorsolateral prefrontal region from healthy individuals.
    Alexander-Kaufman K; Dedova I; Harper C; Matsumoto I
    Neurochem Int; 2007; 51(6-7):433-9. PubMed ID: 17590479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroproteomics - the tasks lying ahead.
    Becker M; Schindler J; Nothwang HG
    Electrophoresis; 2006 Jul; 27(13):2819-29. PubMed ID: 16739225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroproteomics of the synapse and drug addiction.
    Abul-Husn NS; Devi LA
    J Pharmacol Exp Ther; 2006 Aug; 318(2):461-8. PubMed ID: 16644901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder.
    Gogos JA
    Int Rev Neurobiol; 2007; 78():397-422. PubMed ID: 17349868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcellular proteomics.
    Dreger M
    Mass Spectrom Rev; 2003; 22(1):27-56. PubMed ID: 12768603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches to the study of postmortem brain in psychiatric illness: old limitations and new challenges.
    McCullumsmith RE; Meador-Woodruff JH
    Biol Psychiatry; 2011 Jan; 69(2):127-33. PubMed ID: 21094488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in atherosclerosis-based proteomics: new biomarkers and a future perspective.
    Alvarez-Llamas G; de la Cuesta F; Barderas ME; Darde V; Padial LR; Vivanco F
    Expert Rev Proteomics; 2008 Oct; 5(5):679-91. PubMed ID: 18937558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yeast genomics and proteomics in drug discovery and target validation.
    Parsons AB; Geyer R; Hughes TR; Boone C
    Prog Cell Cycle Res; 2003; 5():159-66. PubMed ID: 14593709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research.
    Ekegren T; Hanrieder J; Bergquist J
    J Mass Spectrom; 2008 May; 43(5):559-71. PubMed ID: 18416436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.